Canasa
Generic Name
Mesalamine
Manufacturer
AbbVie (formerly Allergan)
Country
USA
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| canasa 400 mg tablet | ৳ 5.00 | ৳ 50.00 |
Description
Overview of the medicine
Canasa 400 mg (mesalamine) is primarily a rectal suppository, not a tablet, used to treat mild to moderate ulcerative colitis in the rectum and sigmoid colon. Mesalamine is an anti-inflammatory drug that works locally in the bowel to reduce inflammation.
Uses & Indications
Dosage
Adults
One 400 mg rectal suppository two to three times daily. For active disease, often three times daily (total 1200 mg/day). For maintenance, usually one or two times daily.
Elderly
No specific dosage adjustment recommended, but use with caution and monitor renal function, especially in those with pre-existing renal impairment.
Renal_impairment
Use with caution. Monitor renal function closely. Avoid in severe renal impairment.
How to Take
Administer rectally. The suppository should be retained for one to three hours or longer if possible. For optimal results, empty bowels before administration. Do not take orally.
Mechanism of Action
Mesalamine's exact mechanism is not fully understood, but it is believed to act locally in the colon to reduce inflammation. It may inhibit cyclooxygenase (COX) and lipoxygenase pathways, decreasing the production of inflammatory mediators like prostaglandins and leukotrienes. It also reduces neutrophil chemotaxis and free radical production.
Pharmacokinetics
Onset
Therapeutic effects may be observed within a few days to weeks of consistent use.
Excretion
Mainly through the kidneys as N-acetylmesalamine. Some unabsorbed mesalamine is excreted in feces.
Half life
Mesalamine: approximately 0.5-1.5 hours. N-acetylmesalamine (metabolite): 5-10 hours.
Absorption
Following rectal administration, systemic absorption of mesalamine is minimal but varies. For 400 mg suppositories, plasma concentrations are typically low.
Metabolism
Primarily N-acetylation in the intestinal wall and liver to N-acetylmesalamine, which is pharmacologically inactive.
Side Effects
Contraindications
- •Hypersensitivity to mesalamine, salicylates (e.g., aspirin), or any component of the formulation.
- •Severe renal impairment.
Drug Interactions
Lactulose
May interfere with the release of mesalamine from pH-dependent formulations (less relevant for rectal suppository, but general consideration for oral forms).
Azathioprine or Mercaptopurine
Increased risk of myelosuppression (bone marrow depression). Monitor blood counts closely.
Nephrotoxic agents (e.g., NSAIDs)
Increased risk of renal adverse reactions, especially in patients with pre-existing renal dysfunction.
Storage
Store at controlled room temperature, 20-25°C (68-77°F). Protect from moisture and excessive heat. Keep out of reach of children.
Overdose
Overdose is rare with rectal administration due to minimal systemic absorption. Symptoms of oral overdose may include nausea, vomiting, abdominal pain, headache, lethargy. Treatment is supportive and symptomatic.
Pregnancy & Lactation
Pregnancy Category B. Studies in pregnant women have not shown increased risk. Use only if clearly needed. Mesalamine is excreted in breast milk; use with caution during breastfeeding and monitor infant for diarrhea.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture, specific expiry date found on packaging.
Availability
Globally
Approval Status
FDA Approved
Patent Status
Patent Expired, Generics Available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in